Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Gibson

Showing results (941-950 of 986) with videos related to

Pageof 99
Sort By:
Substance Abuse|February 12, 2015
The Use of Technology in Participant Tracking and Study Retention: Lessons Learned From a Clinical Trials Network StudyShannon Gwin Mitchell, Robert P Schwartz, Anika A H Alvanzo, et al.
Hepatology (Baltimore, Md.)|March 27, 2024
Genetic variation in severe cystic fibrosis liver disease is associated with novel mechanisms for disease pathogenesisJaclyn R Stonebraker, Rhonda G Pace, Paul J Gallins, et al.
The European Respiratory Journal|November 18, 2017
Airway microbiota across age and disease spectrum in cystic fibrosisEdith T Zemanick, Brandie D Wagner, Charles E Robertson, et al.
American Journal of Nephrology|March 31, 2021
Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport SyndromeGlenn M Chertow, Gerald B Appel, Sharon Andreoli, et al.
JCI Insight|March 22, 2022
CFTR bearing variant p.Phe312del exhibits function inconsistent with phenotype and negligible response to ivacaftorKaren S Raraigh, Kathleen C Paul, Jennifer L Goralski, et al.
Science (New York, N.Y.)|October 23, 2020
Proximal colon-derived O-glycosylated mucus encapsulates and modulates the microbiotaKirk Bergstrom, Xindi Shan, David Casero, et al.
American Journal of Respiratory and Critical Care Medicine|March 18, 2021
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One <i>F508del</i> AlleleEdith T Zemanick, Jennifer L Taylor-Cousar, Jane Davies, et al.
Kidney International Reports|June 11, 2020
Persistent Disease Activity in Patients With Long-Standing Glomerular DiseaseElisa Delbarba, Maddalena Marasa, Pietro A Canetta, et al.
Thorax|December 16, 2015
US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosisR Andres Floto, Kenneth N Olivier, Lisa Saiman, et al.
Kidney International Reports|December 18, 2019
Treatment Patterns Among Adults and Children With Membranous Nephropathy in the Cure Glomerulonephropathy Network (CureGN)Michelle M O'Shaughnessy, Jonathan P Troost, Andrew S Bomback, et al.
Pageof 99

Showing results (941-950 of 986) with videos related to

Sort By:
Pageof 99
Substance Abuse|February 12, 2015
The Use of Technology in Participant Tracking and Study Retention: Lessons Learned From a Clinical Trials Network StudyShannon Gwin Mitchell, Robert P Schwartz, Anika A H Alvanzo, et al.
Hepatology (Baltimore, Md.)|March 27, 2024
Genetic variation in severe cystic fibrosis liver disease is associated with novel mechanisms for disease pathogenesisJaclyn R Stonebraker, Rhonda G Pace, Paul J Gallins, et al.
The European Respiratory Journal|November 18, 2017
Airway microbiota across age and disease spectrum in cystic fibrosisEdith T Zemanick, Brandie D Wagner, Charles E Robertson, et al.
American Journal of Nephrology|March 31, 2021
Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport SyndromeGlenn M Chertow, Gerald B Appel, Sharon Andreoli, et al.
JCI Insight|March 22, 2022
CFTR bearing variant p.Phe312del exhibits function inconsistent with phenotype and negligible response to ivacaftorKaren S Raraigh, Kathleen C Paul, Jennifer L Goralski, et al.
Science (New York, N.Y.)|October 23, 2020
Proximal colon-derived O-glycosylated mucus encapsulates and modulates the microbiotaKirk Bergstrom, Xindi Shan, David Casero, et al.
American Journal of Respiratory and Critical Care Medicine|March 18, 2021
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One <i>F508del</i> AlleleEdith T Zemanick, Jennifer L Taylor-Cousar, Jane Davies, et al.
Kidney International Reports|June 11, 2020
Persistent Disease Activity in Patients With Long-Standing Glomerular DiseaseElisa Delbarba, Maddalena Marasa, Pietro A Canetta, et al.
Thorax|December 16, 2015
US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosisR Andres Floto, Kenneth N Olivier, Lisa Saiman, et al.
Kidney International Reports|December 18, 2019
Treatment Patterns Among Adults and Children With Membranous Nephropathy in the Cure Glomerulonephropathy Network (CureGN)Michelle M O'Shaughnessy, Jonathan P Troost, Andrew S Bomback, et al.
Pageof 99